News

As Palforzia exits the market on July 31, 2026, allergists Robert Wood, MD, and Jacqueline Ross, MD, outline what changes for patients already in treatment.

Lebrikizumab improved itch, quality of life, and infection rates in kids with moderate-to-severe atopic dermatitis, ADorable-1 results suggest.

New phase 3 ADorable-1 data show lebrikizumab improved skin clearance in children with moderate-to-severe atopic dermatitis.

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.

MV130, a sublingual mucosal trained immunity vaccine, showed significant benefits vs placebo, with benefit sustained after treatment ended.

Benjamin van Boxtel, MD, discusses the importance of familial screening for aortic dissection and the danger of missing potential risk factors.

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.

John Giacona, PhD, PA-C, discusses the cardiology perspective on screening for and managing pulmonary hypertension in interstitial lung disease.

Robert. Wood, MD, discusses post hoc OUTMATCH stage 2 findings on age and maintenance dosing in multiallergen oral immunotherapy.

NYC allergists discuss tapinarof's 80-day treatment-free interval, ruxolitinib's box warning hurdles, and more.

Pfizer reported positive topline phase 3 results, with significant improvements in facial and total repigmentation at week 52 versus placebo.

Moderator Greg Bensch and a panel of allergists discuss itch control, access barriers, and guideline gaps shaping newer AD topicals in this clinical forum.

Phoenix PAH specialists discuss RHC-guided monitoring, sotatercept shunting and erythrocytosis signals, meth-PAH management, and prostacyclin transition strategies.

Pranav Garimella, MD, discusses how GLP-1 receptor agonists are reshaping CKD treatment sequencing alongside SGLT2 inhibitors, RAS inhibitors, and finerenone.

Robert Wood, MD, discusses OUTMATCH data showing omalizumab beat multiallergen oral immunotherapy, though MOIT dropouts narrowed the gap.

Bryan Wells, MD, breaks down new data from 3 universities that have produced a relatively consistent peak systolic velocity, indicating the potential for broad treatment guidelines.

New FARE registry data show epinephrine use and biphasic reactions occur across sesame, seed, and herb/spice allergies, according to Carolyn H. Baloh, MD.

How should clinicians choose atopic dermatitis treatments? Harrison Nguyen, MD, discusses personalized therapy and when to escalate care.

Andrew Adams discusses tegoprubart in kidney transplantation and the phase 2 BESTOW data on kidney function, rejection, and immunosuppression.

PAH specialists discuss prostacyclin use, pericardial effusion risks, erythrocytosis, and what real-world super-responders look like in practice.

Topline data from the largest disease-modification trial in biliary atresia show no benefit over placebo for the primary endpoint, though the established safety profile in approved indications was maintained.

In this episode of The Medical Sisterhood, physician entrepreneurship is explored as Meagen McCusker, MD, shares lessons on private practice, leadership, and career.

Hunter Champion, MD, PhD, covers his experience with furosemide injections in reducing hospital readmissions and how the ReadyFlow may decrease them further.

In the OUTMATCH stage 2 randomized trial, omalizumab achieved greater intention-to-treat success than multiallergen oral immunotherapy.

A FARE Patient Registry analysis finds herb and spice allergies disproportionately affect Black, Hispanic, and lower-income patients, Carolyn Baloh, MD, says.

World Hepatitis Day survey findings reveal gaps in chronic hepatitis B awareness and liver cancer risk perception, with Cary James discussing elimination efforts.

How is drug selection evolving in atopic dermatitis? Walter Liszewski, MD, discusses personalized therapy and long-term care.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.